| Item Type | Name |
|
Concept
|
Biomarkers, Tumor
|
|
Concept
|
Biomarkers
|
|
Academic Article
|
CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
|
|
Academic Article
|
Impact of cardiovascular comorbidity on ovarian cancer mortality.
|
|
Academic Article
|
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
|
|
Academic Article
|
Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma.
|
|
Academic Article
|
The complexity of tumor vascularity.
|
|
Academic Article
|
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
|
|
Academic Article
|
Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.
|
|
Academic Article
|
Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients.
|
|
Academic Article
|
Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
|
|
Academic Article
|
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer.
|
|
Academic Article
|
Platelet-derived growth factor receptor alpha (PDGFRa) targeting and relevant biomarkers in ovarian carcinoma.
|
|
Academic Article
|
Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
|
|
Academic Article
|
Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer.
|
|
Academic Article
|
Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion.
|
|
Academic Article
|
Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma.
|
|
Academic Article
|
Markers of angiogenesis in ovarian cancer.
|
|
Academic Article
|
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
|
|
Academic Article
|
MicroRNAs in body fluids--the mix of hormones and biomarkers.
|
|
Academic Article
|
Prognostic biomarkers in ovarian cancer.
|
|
Academic Article
|
Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.
|
|
Academic Article
|
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.
|
|
Academic Article
|
EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.
|
|
Academic Article
|
Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.
|
|
Academic Article
|
A novel platform for detection of CK+ and CK- CTCs.
|
|
Academic Article
|
Inverse relationship between TCTP/RhoA and p53 /cyclin A/actin expression in ovarian cancer cells.
|
|
Academic Article
|
Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR.
|
|
Academic Article
|
Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer.
|
|
Academic Article
|
Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.
|
|
Academic Article
|
Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.
|
|
Academic Article
|
The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression.
|
|
Academic Article
|
Differential platelet levels affect response to taxane-based therapy in ovarian cancer.
|
|
Academic Article
|
Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.
|
|
Academic Article
|
Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
|
|
Academic Article
|
Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer.
|
|
Academic Article
|
Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
|
|
Academic Article
|
Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
|
|
Academic Article
|
Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis.
|
|
Academic Article
|
Role of Increased n-acetylaspartate Levels in Cancer.
|
|
Academic Article
|
miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.
|
|
Academic Article
|
Highly heterogeneous genomic landscape of uterine leiomyomas by?whole exome sequencing and genome-wide arrays.
|
|
Academic Article
|
Cancer Epidemiology Biomarkers and Prevention
|
|
Academic Article
|
Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.
|
|
Academic Article
|
Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.
|
|
Academic Article
|
Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
|
|
Academic Article
|
A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients.
|
|
Academic Article
|
Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.
|
|
Academic Article
|
Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.
|
|
Academic Article
|
Association of Ovarian Tumor ?2-Adrenergic Receptor Status with Ovarian Cancer Risk Factors and Survival.
|
|
Academic Article
|
Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA).
|
|
Academic Article
|
The rise of genomic profiling in ovarian cancer.
|
|
Academic Article
|
Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery.
|
|
Academic Article
|
Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
|
|
Academic Article
|
Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.
|
|
Academic Article
|
Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs.
|
|
Academic Article
|
DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer.
|
|
Academic Article
|
Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
|
|
Academic Article
|
Perioperative inhibition of ?-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome.
|
|
Academic Article
|
Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer.
|
|
Academic Article
|
PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.
|
|
Academic Article
|
Bioactive lipid metabolism in platelet "first responder" and cancer biology.
|
|
Academic Article
|
Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells.
|
|
Academic Article
|
Advancing Drug Development in Gynecologic Malignancies.
|
|
Academic Article
|
Clinical and biological significance of EZH2 expression in endometrial cancer.
|
|
Academic Article
|
A Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer.
|
|
Academic Article
|
Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.
|
|
Academic Article
|
Mechanisms of nuclear content loading to exosomes.
|
|
Academic Article
|
Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum.
|
|
Academic Article
|
NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.
|
|
Academic Article
|
The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis.
|
|
Academic Article
|
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
|
|
Academic Article
|
Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
|
|
Academic Article
|
Combined VEGFR and MAPK pathway inhibition in angiosarcoma.
|
|
Academic Article
|
Novel Markers for Liquid Biopsies in Cancer Management: Circulating Platelets and Extracellular Vesicles.
|
|
Academic Article
|
Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex.
|
|
Academic Article
|
Biobehavioral factors predict an exosome biomarker of ovarian carcinoma disease progression.
|
|
Academic Article
|
The biology of hope: Inflammatory and neuroendocrine profiles in ovarian cancer patients.
|
|
Academic Article
|
EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.
|